This week in techniques Approach Summary Licensing status Publication and contact information Disease models Fibrillin 1 (Fbn1)-mutant mouse models of systemic scleroderma Mice harboring mutations in the integrin-binding domain of Fbn1 could help model systemic...

arGentis received exclusive, worldwide rights to the university's ARG301 to treat rheumatoid arthritis. The oral synthetic peptide targeting Type II collagen is in preclinical development. Financial terms were not disclosed. arGentis' ARG201 type I native...

EMEA granted Orphan Drug designation for arGentis' ARG201 to treat diffuse systemic sclerosis. The type I native bovine collagen , which also has Orphan designation in the U.S., has completed a Phase II trial for the...

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for ARG201 to treat systemic sclerosis. arGentis has completed a Phase II trial of the type I native bovine...

In 1H09, arGentis will begin 2 identical, double-blind, international Phase III trials of oral ARG201. Each trial will enroll about 125 late phase patients. ARG201 has Orphan Drug designation in the U.S. arGentis Pharmaceuticals LLC...

In a double-blind, U.S. Phase II trial in 168 patients, oral ARG201 missed the primary endpoint of a significant improvement in MRSS vs. placebo. In a prospectively defined subgroup of late phase patients (diagnosed from...

FDA granted Orphan Drug designation for ARG201 to treat diffuse systemic sclerosis. arGentis has completed a Phase II trial of the solubilized type I native bovine collagen for the indication. arGentis Pharmaceuticals LLC , Memphis, Tenn....

arGentis received an exclusive, worldwide license to the university's ARG201 , a solubilized type I native bovine collagen, to treat systemic sclerosis and other fibrosing diseases. Last year, ARG201 completed a Phase II trial to treat...